TargetRadar
TargetRadar: Drug Target Validation in 30 Seconds Enterprise tools cost $50-200K/year and take weeks.
Core trick
Queries seven biomedical databases and combines their evidence into a weighted seven-dimension score per drug target.
Description
TargetRadar: Drug Target Validation in 30 Seconds
Enterprise tools cost $50-200K/year and take weeks. TargetRadar delivers comprehensive analysis—free, instant, open source.
FEATURES:
• 7-Dimension Scoring: Genetic Evidence, Chemical Tractability, Structural Readiness, Clinical History, Regulatory Genomics (AlphaGenome), Literature, Innovation—querying Open Targets, ChEMBL, PDB, ClinicalTrials.gov, Ensembl, PubMed, bioRxiv
• 16 AI Features (Opus 4.6): Intelligence briefs, competitive analysis, hypothesis generation, conflict detection, trial design
• Tools: Molecule Testing Lab, DeepTarget Discovery, 3D visualization, docking, .docx/.xlsx reports
Live: http://138.68.7.97:4000
MIT licensed, no login required.
README excerpt
# TargetRadar **Drug Target Validation in 30 Seconds** [](LICENSE) [](CHANGELOG.md) [](https://nextjs.org) [](https://typescriptlang.org) [](https://github.com/google-deepmind/alphagenome_research) --- ## The Problem Drug target validation requires querying 7+ specialized databases, years of domain expertise to interpret results, and weeks of manual work to compile a report. Enterprise tools like Clarivate or Informa Pharma Intelligence cost **$50-200K/year**. Academic researchers, biotech startups, patient advocates, and science journalists are **locked out**. ## The Solution **TargetRadar puts enterprise-grade target validation in everyone's hands -- free, open source, in 30 seconds.** Search any gene target. Get a comprehensive **7-dimension analysis** -- including **AlphaGenome-powered regulatory genomics** -- with real-time data from public APIs, AI-powered scientific narratives, and professional downloadable reports. No account needed. No paywall. --- ## Who Is This For? - **PhD Students** -- Choose thesis targets with confidence - **Biotech Investors** -- Due diligence on target pipelines - **Academic Labs** -- Prioritize new research